Telix Pharmaceuticals Ltd (TLX) income statement
TLXNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as TLPPF
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Feb 20, 2026Score 3/30
$8.96+0.11 (+1.19%)
Close on Nov 18, 2026Market cap $3.04BP/E –Yield –
Telix Pharmaceuticals Ltd income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY2025
- Gross margin
- 53.1%
- Operating margin
- 3.7%
- Net margin
- -0.9%
- Return on equity, FY2025
- –
Financial strength
- Current ratio
- 2.01
- Debt to equity
- –
- Debt to assets
- 37.9%
- Cash to current liabilities
- 103.9%
Valuation
- P/E ratio
- –
- Price to sales
- 3.78
- Price to book
- –
- Dividend yield
- –
See a number that looks wrong?